You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

KNOXVILLE, Tenn., Jan. 26, 2021 /PRNewswire/ --Integrity Laboratories announced today, the launch of the first commercially available quantitative index to accompany positive COVID-19 specimen resulted through their EUA approved platform. The feature, known as AmpliteCt, is a viral load indicator (VLI) and is achieved through an automated, quantitative methodology that categorizes the concentration of viral genetic material in a patient specimen. The AmpliteCt algorithm leverages several key data points, including cycle threshold (Ct), to accurately stratify COVID-19 positive patients within low, moderate, or high infection designations. Continue Reading Maria Cekanova, RNDr, Ph.D, Chief Scientific Officer for Integrity Laboratories. Christian Clevenger, Integrity Laboratories Chief Executive Officer "The AmpliteCt Viral Load Indicator utilizes the ability of a real time reverse transcriptase polymerase chain reaction (RT-PCR) technology to quantify the pathogen's genetic material in a patient sample in a very short time with high sensitivity and specificity, "saidMaria Cekanova, RNDr, Ph.D, Chief Scientific Officer for Integrity Laboratories. "We are excited to begin deploying this much needed advancement in technology to our healthcare partners." AmpliteCt VLI was developed by GenomIQ, a division of Integrity Laboratories focused on research and innovation of novel diagnostic technologies. Work began on the quantitative based approach to COVID-19 in September and was accelerated in conjunction with existing healthcare partnerships and validation studies. "The AmpliteCt technology advancement into viral load visibility is game changing for clinicians as they seek to triage the clinical needs of their patients," Said Christian Clevenger, Integrity Laboratories Chief Executive Officer. "Having access to quantifiable indexing also helps to identify those that may be candidates for viral load mediated therapies such as convalescent plasma. We are very proud of our team and their pioneering work in advancing diagnostic accuracy for COVID-19." ABOUT INTEGRITY LABORATORIESIntegrity Laboratoriesis the leading biotechnology firm committed to modernizing infectious disease management through high-complexity clinical diagnostics. Integrity Laboratories has pioneered antimicrobial stewardship with the introduction of Intercept PCR, a molecular diagnostics platform that enables providers to ordersame-dayandnext-daydiagnostic data on complicated patient conditions throughnon-invasivemethods. Integrity Laboratories partners with the most trusted healthcare systems, providers, and insurance networks to deliver best-in-class technologies that lower costs and improve outcomes.Media Contact: Kelly Allen [emailprotected] 1-844-658-5745 x110SOURCE Integrity Laboratories Related Links http://www.integritylaboratories.com

Answer: Integrity Laboratories Launches Novel Quantification Tool for COVID-19 Providers Knoxville Based Biotechnology Firm Introduces Newest Technology Helping Providers Diagnose and Treat COVID-19 with Greater Efficiency